Literature DB >> 35840694

Fetal uropathies: pre- and postnatal imaging, management and follow-up.

Marie Cassart1.   

Abstract

Congenital uropathies are the most common fetal anomalies. They include a wide spectrum of anomalies ranging from mild pelvis dilation to complex urinary tract malformations. Prenatal imaging not only allows for their diagnosis but, in experienced hands, it can differentiate obstructive from refluxing or malformative uropathies. Such precise prenatal information allows for intervention before birth in select cases or for adapting the postnatal workup to provide a better long-term outcome. For the different types of congenital uropathies, we describe their prenatal presentations on US and the complementary role of fetal MRI where indicated. We correlate these findings with postnatal workup and summarize the updated neonatal diagnostic and clinical/surgical management.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Congenital anomalies; Fetus; Kidneys; Postnatal workup; Prenatal ultrasound; Ultrasound; Urinary tract

Year:  2022        PMID: 35840694     DOI: 10.1007/s00247-022-05433-4

Source DB:  PubMed          Journal:  Pediatr Radiol        ISSN: 0301-0449


  53 in total

1.  The magnitude of fetal renal pelvic dilatation can identify obstructive postnatal hydronephrosis, and direct postnatal evaluation and management.

Authors:  Douglas E Coplen; Paul F Austin; Yan Yan; Valerie M Blanco; Jeffrey M Dicke
Journal:  J Urol       Date:  2006-08       Impact factor: 7.450

2.  The antenatally detected pelvi-ureteric junction stenosis: advances in renography and strategy of management.

Authors:  Khalid Ismaili; Amy Piepsz
Journal:  Pediatr Radiol       Date:  2013-03-24

Review 3.  Surgery versus non-surgical management for unilateral ureteric-pelvic junction obstruction in newborns and infants less than two years of age.

Authors:  Marcus Weitz; Suniva Portz; Guido F Laube; Joerg J Meerpohl; Dirk Bassler
Journal:  Cochrane Database Syst Rev       Date:  2016-07-14

4.  Causes of renal oligohydramnios: impact on prenatal counseling and postnatal outcome.

Authors:  Sebastian Loos; Markus J Kemper
Journal:  Pediatr Nephrol       Date:  2017-11-11       Impact factor: 3.714

5.  Can severely impaired cortical transit predict which children with pelvi-ureteric junction stenosis detected antenatally might benefit from pyeloplasty?

Authors:  Amy Piepsz; Marianne Tondeur; Cécile Nogarède; Frank Collier; Khalid Ismaili; Michelle Hall; André Dobbeleir; Hamphrey Ham
Journal:  Nucl Med Commun       Date:  2011-03       Impact factor: 1.690

Review 6.  Primary non-surgical management of unilateral ureteropelvic junction obstruction in children: a systematic review.

Authors:  Marcus Weitz; Maria Schmidt; Guido Laube
Journal:  Pediatr Nephrol       Date:  2016-12-23       Impact factor: 3.714

7.  Long-term follow-up and management of prenatally detected, isolated hydronephrosis.

Authors:  Yi Yang; Ying Hou; Zhi Bin Niu; Chang Lin Wang
Journal:  J Pediatr Surg       Date:  2010-08       Impact factor: 2.545

Review 8.  2021 update on the urinary tract dilation (UTD) classification system: clarifications, review of the literature, and practical suggestions.

Authors:  Hiep T Nguyen; Andrew Phelps; Brian Coley; Kassa Darge; Audrey Rhee; Jeanne S Chow
Journal:  Pediatr Radiol       Date:  2022-01-04

9.  High frequency of kidney and urinary tract anomalies in asymptomatic first-degree relatives of patients with CAKUT.

Authors:  Burcu Bulum; Z Birsin Ozçakar; Evren Ustüner; Ebru Düşünceli; Aslı Kavaz; Duygu Duman; Katherina Walz; Suat Fitoz; Mustafa Tekin; Fatoş Yalçınkaya
Journal:  Pediatr Nephrol       Date:  2013-06-28       Impact factor: 3.714

10.  A long-term follow-up in conservative management of unilateral ureteropelvic junction obstruction with poor drainage and good renal function.

Authors:  S Arena; R Chimenz; E Antonelli; F M Peri; P Romeo; P Impellizzeri; C Romeo
Journal:  Eur J Pediatr       Date:  2018-09-12       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.